Eloxx Pharmaceuticals has received FDA clearance to proceed with clinical trials for Exaluren, a potential treatment for ADPKD. The Phase 2 trial will enroll about 60 patients, with results expected in 2029.

Reported Thursday, Oct 29 - 8:04am EDT (TheFly subscription required to read more.)

Eloxx Pharmaceuticals is set to present its innovative kidney disease treatments at the upcoming Guggenheim Healthcare Innovation Conference, led by CEO Sumit Aggarwal.

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

Eloxx Pharmaceuticals has finalized the design for its Phase 2 EXPRESS study in ADPKD, appointing Dr. T.R. Srinivas as Chief Medical Officer to enhance its clinical strategies.

Eloxx Pharmaceuticals has dosed the first two patients in its Phase 2b EXACT study. This global clinical trial evaluates exaluren as a treatment for nonsense mutation Alport syndrome (NMAS). The trial focuses on the underlying genetic causes of the condition, as there are currently no FDA-approved,

Eloxx Pharmaceuticals has initiated its Phase 2b clinical trial of Exaluren for treating nonsense mutation Alport syndrome, marking a crucial advance in kidney disease treatment.

Eloxx Pharmaceuticals (ELOX) has dosed the first two patients in the EXACT Study, a Phase 2b trial of exaluren in nonsense mutation Alport syndrome (NMAS).The study is evaluating exaluren in patients whose Alport syndrome is driven by nonsense mutations, a group for which there is currently no FDA-approved therapy targeting the underlying genetic cause. The company expects topline data from the initial 16-week placebo-controlled portion of the study in mid‑2027, with a final readout anticipated by the end of 2027. Company leadership and external clinical experts describe this as an important step for an underserved patient population that can progress to kidney failure in early adulthood.

Completed underwritten public offering with gross proceeds of $66.0 million and uplisting to the Nasdaq Capital Market, significantly strengthening the Company's balance sheet Phase 2b clinical trial of exaluren in nonsense mutation Alport syndrome expected to initiate in the third...

Eloxx Pharmaceuticals has reported a significant financial boost with a recent public offering and Nasdaq uplisting, facilitating clinical progress in kidney disease treatments.

ARLINGTON, Mass., Aug. 12, 2026 /PRNewswire/ -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for

Eloxx Pharmaceuticals (Nasdaq: ELOX) reported second quarter 2026 results and a major strengthening of its capital position following a completed underwritten public offering with $66.0 million in gross proceeds and uplisting to the Nasdaq Capital Market. Net proceeds were approximately $58.3 million, contributing to $62.0 million in cash and cash equivalents as of June 30, 2026, which the company expects will fund operations into mid‑2028 and through data readouts for exaluren in Alport syndrome and ADPKD.Eloxx obtained FDA clearance to proceed with a Phase 2b trial of exaluren in nonsense mutation Alport syndrome, targeted to start in the third quarter of 2026, with topline 16‑week data expected by mid‑2027. Exaluren has orphan drug designation for Alport syndrome in the US and EU, and in July 2026 the European Commission granted orphan designation for exaluren in ADPKD. A Phase 2 ADPKD trial is planned for 2027. Second quarter 2026 net loss was $4.5 million, compared with $1.9 million a year earlier, driven by higher R&D and G&A expenses as clinical and corporate activities expanded.